Showing results (171-180 of 215) with videos related to

Sort By:
Pageof 22
Urology|April 11, 2001
Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancerG J Kelloff, R Lieberman, V E Steele, et al.
Journal of Cellular Biochemistry. Supplement|January 1, 1994
Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer InstituteG J Kelloff, J A Crowell, C W Boone, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 1, 1995
Approaches to the development and marketing approval of drugs that prevent cancerG J Kelloff, J R Johnson, J A Crowell, et al.
British Journal of Cancer|October 15, 2014
Effects of α-tocopherol and β-carotene supplementation on liver cancer incidence and chronic liver disease mortality in the ATBC studyG Y Lai, S J Weinstein, P R Taylor, et al.
Journal of the National Cancer Institute|May 1, 1986
Multiple markers for lung cancer diagnosis: validation of models for advanced lung cancerM H Gail, L Muenz, K R McIntire, et al.
Lancet (London, England)|July 4, 1998
Spectrum of AIDS-associated malignant disordersJ J Goedert, T R Coté, P Virgo, et al.
Journal of the National Cancer Institute|March 16, 1988
Multiple markers for lung cancer diagnosis: validation of models for localized lung cancerM H Gail, L Muenz, K R McIntire, et al.
Scandinavian Journal of Infectious Diseases|October 24, 2001
Helicobacter pylori infection in rural China: exposure to domestic animals during childhood and adulthoodL M Brown, T L Thomas, J L Ma, et al.
American Journal of Epidemiology|September 15, 1995
Interplay between design and analysis for behavioral intervention trials with community as the unit of randomizationS B Green, D K Corle, M H Gail, et al.
Hepatology (Baltimore, Md.)|July 27, 1999
Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1Z Sun, P Lu, M H Gail, et al.
Pageof 22